PulmCCM - Page 3 of 41 - All the best in pulmonary & critical care
Advertisement
Apr 032014
 
FDA warns against doripenem (Doribax) for ventilator-associated pneumonia

FDA Warning on Doripenem (Doribax) for VAP In March 2014, the FDA issued a warning statement against Doribax (doripenem) for ventilator associated pneumonia, saying: Doribax carries an increased risk of death and lower clinical cure rates compared to use of imipenem and cilastatin … Doribax is not approved to treat any type of pneumonia. (Doripenem is approved [… read more]

Mar 292014
 
No benefit from higher mean arterial pressure in most with septic shock

In Septic Shock, Goal of MAP > 65 mm Hg Remains Standard by Abhishek Biswas, MD In the 13 years since Rivers et al published their seminal paper that established “early goal directed therapy” for sepsis as the standard of care, treatment for severe sepsis and septic shock have evolved dramatically. Newer research questions the wisdom [… read more]

Mar 252014
 

May 10th and 11th (pre-congress courses on may 9th), Montreal. Great speakers, great topics, great city, great weather (well…hopefully no snow!). Do you know how to use ultrasound to help you diagnose or manage coma, bowel obstruction, CHF, dyspnea, swollen joints and renal failure, among other things?  No matter how good you are at the [… read more]

Mar 212014
 
Early goal directed therapy does not improve outcomes in septic shock (ProCESS)

Can we finally “Just Say No” to the mandatory use of central venous catheters and central venous saturation in severe sepsis and septic shock? by Muhammad Adrish, MD In a single center study published in 2001, Rivers et al reported that patients with severe sepsis and septic shock had significantly lower mortality (30.5% vs 46.5%) [… read more]

Mar 162014
 
Beta blockers safe for most patients with asthma or COPD?

Beta-Blockers: Safe (and Effective?) for Most Patients with Asthma, COPD Once upon a time in 1964, it was noted that propranolol, a nonselective beta-blocker, could precipitate severe bronchospasm in patients with asthma, especially at high doses. Additional small studies showed propranolol and other nonselective beta blockers could increase airway resistance. British guidelines advise avoiding beta [… read more]

Mar 162014
 
Bleeding and Coagulation Disorders in the ICU (Review)

Because coagulopathies (an impairment of blood clotting), thrombotic states, and bleeding are all interrelated through the coagulation cascade, and because they occur often in critically ill patients, it makes sense to consider these bleeding and clotting disorders together. That’s what Beverly Hunt did in a review in the February 27 2014 New England Journal of [… read more]

Mar 082014
 
Community Acquired Pneumonia (Review)

Community-acquired pneumonia (CAP) is “ordinary” pneumonia, usually (but not always) caused by one of a short list of pathogens susceptible to common antibiotics. Pneumonia remains one of the main reasons for hospital admissions, and causes an estimated 3.5 million deaths yearly, including more than 50,000 in the U.S. Catching pneumonia also increases the risk for [… read more]

Mar 012014
 
Resuscitation Fluids in Critical Illness (Review)

Resuscitation fluids may be the most common intervention in critical care, with more than 200 million liters of normal saline infused each year in the U.S. alone. However, there is scarce evidence to guide the best use of resuscitation fluids in the ICU. John Myburgh and Michael Mythen’s review article in the September 26 2013 [… read more]

Feb 282014
 
Bloggers correct the New England Journal on ICU decontamination article

Blogger Peer Review Corrects NEJM Article’s Error In June 2013, PulmCCM unquestioningly reported the results of a major randomized trial in the New England Journal of Medicine by Susan S. Huang et al, showing that decontaminating patients upon arrival to the ICU with chlorhexidine baths and nasal mupirocin resulted in a dramatic drop in nosocomial infections [… read more]

Feb 232014
 
Critical Care Roundup: Issue #1

Welcome to issue #1 of the Critical Care Roundup, a new occasional feature on PulmCCM. Here we’ll touch briefly on all the interesting stuff there wasn’t time to thoroughly review. Got a study that should go in the next roundup? Post a link in the comments or by emailing [email protected] Or, browse all the PulmCCM [… read more]

Feb 222014
 
Epitaph for nitric oxide for ARDS

Image: Dartmouth Nitric Oxide: No Benefit Even in Severe ARDS Giving inhaled nitric oxide to people with acute respiratory distress syndrome (ARDS) improves oxygenation, but has never been demonstrated to improve survival. Not many physicians seem to use nitric oxide for ARDS anymore, except possibly as salvage therapy in life-threatening refractory disease. Even that well-meaning [… read more]

Feb 202014
 
Sublobar resections as good as lobectomy for stage IA GGO lung cancer?

The new USPSTF lung cancer screening guidelines are about to produce an enormous wave of abnormal chest CTs, with suspicious pulmonary nodules in millions of current and former U.S. smokers. Many will be surgically removed, and thousands of people will be saved from premature death from lung cancer. That’s great news — mostly. Less widely [… read more]

Feb 162014
 
PulmCCM Journal Launches: Your Submissions Welcome

Dear colleagues, I am excited to announce the launch of PulmCCM Journal, a new online, open access, peer-reviewed journal serving the practicing physician in critical care and respiratory medicine. PulmCCM Journal’s primary mission will be publishing high-quality, highly useful reviews of important clinical topics to improve decision-making and the quality of care worldwide. Case reports, [… read more]

Feb 152014
 
Tight glycemic control in critically ill kids: benefits, risks still unclear

Intensive insulin therapy for critically ill adults was rapidly adopted as standard care after 2001 when an apparent benefit was established after cardiac surgery, then medical ICU patients. Eleven years later, after a wave of minor harm signals, the NICE-SUGAR study confirmed for most intensivists that the excess hypoglycemia from intensive glucose control was potentially lethal in adults, and [… read more]

Feb 112014
 
Vitamin D: no relationship to COPD exacerbations

After a stupefying amount of research on vitamin D — with 70 vitamin D studies published in PubMed in January 2014 alone — there is no consistent signal tying vitamin D supplementation to improvement in any health condition. A recent “futility analysis” (a form of meta-analysis) of 40 randomized trials suggests vitamin D does not [… read more]

Feb 092014
 
Should limited email ads finance PulmCCM's future? SURVEY RESULTS

Hello colleagues, PulmCCM has been doing great traffic-wise, but that hasn’t translated into financial health. PulmCCM took a net loss for 2013 as it has each year. That’s OK — making money has never been what this project is about. However, PulmCCM does need continuous funding to thrive and grow into its full potential. My [… read more]

Feb 092014
 
Sedation and Analgesia in the Critically Ill (Review)

Pain, agitation, and delirium are all extremely common in ICU patients–so much so that they’ve been termed the “ICU triad.” No one knows exactly how common each is, because ICU patients are often too delirious to complain of pain; or their agitation hides their delirium; or their unidentified pain may cause their agitation; or …. [… read more]

Feb 042014
 
Can pulmonologists do their own on-site cytopathology during bronchoscopy?

On-site, intra-procedure cytopathologic examination of aspirated tissue during transbronchial needle aspiration (either by EBUS or “blind” approach) is probably helpful during bronchoscopy. Why wouldn’t it be? You’ve got a trained professional there to tell you when you’ve made the diagnosis and can stop taking biopsies. Diagnostic yield should go up, complications down. Randomized trials have [… read more]

Feb 012014
 
Spiriva and heart attack risk: new safety kerfuffle

Last year, PulmCCM reported on the TIOSPIR safety trial comparing the Spiriva dry-powder HandiHaler against the Respimat mist-delivery device. TIOSPIR showed no difference in all-cause mortality or composite cardiovascular risk endpoints between either Spiriva preparation. But this week, a group of drug safety researchers report their granular analysis of TIOSPIR data shows the Respimat device [… read more]